Diabetes

CAMP HILL, Pa. — Rite Aid experienced stronger sales in third quarter 2012 as it expanded its Wellness+ loyalty card program and saw continued growth in flu immunizations and the Wellness store format, the company said Thursday.

HAMILTON, Ontario — Short bursts of exercise appear to lower blood sugar in people with Type 2 diabetes, researchers at Canada's McMaster University have found.

DUBAI — A study conducted by Bristol-Myers Squibb and AstraZeneca found that adding an investigational compound to an existing Type 2 diabetes treatment may help reduce blood-glucose levels among patients.

LONDON — New research on a rare genetic disorder in which the pancreas fails to grow could shed light on how the organ develops and lead to treatments for Type 1 diabetes.

In a study published in the journal Nature Genetics, an international team of researchers led by scientists at England's University of Exeter discovered a genetic mutation present in 15-in-27 people with a condition called pancreatic agenesis, finding a key role for the gene, GATA6, in the development of pacreatic cells.

INDIANAPOLIS — Drug maker Eli Lilly has expanded its Spanish-language portal, the company said Friday.

Subsidiary Lilly USA launched an expanded "En Español" section of the Lilly For Better Health website. The section features a 60-page interactive health album that provides tips on healthy eating, physical activity and managing health conditions, as well as health-and-wellness quizzes and risk assessments on weight management, diabetes and other topics.

CHEVY CHASE, Md. — A recent study of obese and nonobese children found that low vitamin D levels are significantly more prevalent in obese children and are associated with risk factors for Type 2 diabetes. This study was accepted for publication in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism.

DUBAI, United Arab Emirates — A combination of two insulins made by Novo Nordisk reduced abnormally low blood sugar in diabetes patients, according to study results presented at a medical conference.

INDIANAPOLIS — A drug currently under clinical development for Type 2 diabetes produced "meaningful" reductions in blood sugar, according to results of a late-stage clinical study.

Eli Lilly & Co. and Boehringer Ingelheim announced results of a 24-week, open-label arm of a phase-3 study of the investigational drug linagliptin combined with the generic drug metformin, presenting results at the International Diabetes Federation World Diabetes Conference in Dubai.